A cystic fibrosis (CF) pulmonary exacerbation is an acute worsening of respiratory symptoms — including increased cough, sputum production/color change, dyspnea, fatigue, anorexia, and fever — accompanied by a decline in lung function (≥10% drop in FEV₁ from baseline), requiring escalation of antibiotic therapy and airway clearance. [1-3] No universally accepted diagnostic definition exists, but the Fuchs criteria are the most widely used clinical and research framework. [1]
1. History
- Key HPI questions: Baseline FEV₁ and recent trend; change in cough frequency, sputum volume, color, or consistency; new or worsening dyspnea; exercise intolerance; hemoptysis (quantify volume); fever; weight loss; anorexia; fatigue/malaise [1][3]
- Timing: Onset relative to last clinic visit, last exacerbation, and last course of antibiotics; seasonal/viral triggers [4]
- Adherence: Compliance with airway clearance, inhaled antibiotics, mucolytics (dornase alfa, hypertonic saline), pancreatic enzymes, and CFTR modulators (elexacaftor-tezacaftor-ivacaftor) [5]
- Important negatives: Chest pain (pneumothorax), large-volume hemoptysis, sinus symptoms, GI symptoms (distal intestinal obstruction syndrome [DIOS]), recent travel or sick contacts
2. Alarm Features
- Massive hemoptysis (>240 mL) — occurs in ~4.1% of CF patients over a lifetime; requires ICU admission and possible bronchial artery embolization [6-7]
- Pneumothorax — annual incidence ~0.64%; more common in advanced disease; presents with acute pleuritic pain and dyspnea [6][8]
- Acute respiratory failure — hypoxemia (SpO₂ <90%), hypercapnia, accessory muscle use, altered mental status [9-10]
- Significant FEV₁ decline (>20% from baseline) or failure to recover after treatment [11]
- New oxygen requirement at rest or with exertion [7]
3. Medications
- Acute treatment:
- IV antibiotics: most commonly an aminoglycoside (tobramycin) + a β-lactam (piperacillin-tazobactam, ceftazidime, meropenem) — tailored to the patient's most recent sputum culture [11-13]
- Mild exacerbations: oral ciprofloxacin may be trialed first [1]
- Duration: 10–14 days is standard; a large RCT (n=982) demonstrated 10 days was noninferior to 14 days in patients who improved by day 7–10, and 21 days was not superior to 14 days in non-responders [14]
- Continue chronic therapies during exacerbation: dornase alfa, hypertonic saline, azithromycin, inhaled tobramycin (though concomitant inhaled + IV aminoglycosides require caution regarding nephrotoxicity and drug level interpretation) [3]
- CFTR modulators (elexacaftor-tezacaftor-ivacaftor): should be continued; these reduce exacerbation rates by ~63%. In the HEMT era, exacerbations may present more subtly [5][14-15]
- Cautions: Hold high-dose ibuprofen during IV aminoglycoside therapy due to nephrotoxicity risk; monitor aminoglycoside levels closely [3]
4. Diet
- High-calorie, high-protein diet is recommended during exacerbations to counteract increased energy expenditure and catabolism [14][16]
- Ensure adequate pancreatic enzyme replacement with all meals and snacks [17]
- Hydration is critical — dehydrated mucus is a hallmark of CF pathophysiology; encourage liberal fluid intake [2]
- Fat-soluble vitamin supplementation (A, D, E, K) should continue [18]
- In the HEMT era, the traditional "legacy" high-fat diet is being reconsidered in favor of nutrient-dense foods for patients at healthy weight, but during acute exacerbation, caloric optimization remains the priority [19]
5. Review of Systems
- Pulmonary: Cough, sputum changes, dyspnea, hemoptysis, chest pain, wheeze, exercise tolerance
- ENT: Sinus pain/pressure, nasal drainage changes (sinusitis is common) [1]
- GI: Abdominal pain/distension (DIOS, constipation), steatorrhea, appetite changes
- Endocrine: Polyuria/polydipsia (CF-related diabetes worsens during exacerbations; glucose intolerance increases and insulin requirements rise) [3]
- Musculoskeletal: Bone pain (osteoporosis risk)
- Psychiatric: Depression, anxiety, treatment fatigue — annual screening recommended for age ≥12 [14]
6. Collateral History and Family History
- Collateral: Confirm adherence to home therapies; caregiver observations of activity level, appetite, sleep quality; school/work absenteeism [20]
- Family history: CF genotype (F508del homozygous vs. heterozygous); family members with CF (infection control implications — patient-to-patient transmission documented) [18]
- Social context: Home resources for potential outpatient IV therapy (reliable utilities, caregiver availability, financial resources) [3]
7. Risk Factors
- Chronic Pseudomonas aeruginosa colonization — most significant risk factor for exacerbations and lung function decline [13]
- MRSA colonization [18]
- Non-adherence to airway clearance, inhaled antibiotics, or CFTR modulators [2]
- CF-related diabetes — associated with more severe exacerbations [1]
- Low BMI/malnutrition [7]
- Advanced lung disease (low baseline FEV₁) [10]
- Aspergillus fumigatus colonization or ABPA [16]
- Non-tuberculous mycobacteria (NTM) infection, especially M. abscessus [12][21]
- Viral respiratory infections — identified in ~22% of exacerbations and associated with greater FEV₁ decline [4]
8. Differential Diagnosis
- Pneumothorax — acute onset pleuritic chest pain, absent breath sounds; CXR diagnostic [6][8]
- Massive hemoptysis — may mimic or complicate exacerbation [6]
- Allergic bronchopulmonary aspergillosis (ABPA) — therapy-resistant obstruction, elevated IgE, eosinophilia, characteristic imaging [16]
- NTM infection — insidious decline, may not respond to standard anti-pseudomonal therapy [21]
- Pulmonary embolism — consider in patients with PICC lines/central venous access
- Heart failure/pulmonary hypertension — in advanced CF lung disease [14]
- DIOS — abdominal pain mimicking surgical abdomen
- Medication non-adherence presenting as worsening symptoms without true infectious exacerbation [2]
9. Past Medical History
- Baseline FEV₁ and recent spirometry trend — essential for comparison [3][12]
- Sputum microbiology — most recent culture and sensitivities (Pseudomonas, MRSA, Burkholderia, NTM) [18][21]
- Frequency of prior exacerbations and response to previous antibiotic regimens
- Prior pneumothorax or hemoptysis episodes [6]
- CF-related diabetes, liver disease, osteoporosis [14]
- CFTR genotype and current modulator therapy [14]
- Allergies — particularly to β-lactams and aminoglycosides [13]
- Transplant status — post-transplant patients require different management [13]
10. Physical Exam
- Vitals: Tachypnea, tachycardia, fever (>38°C), hypoxemia (SpO₂), weight (compare to baseline) [1][20]
- Pulmonary: New crackles, rhonchi, wheezing, decreased air entry; increased work of breathing, accessory muscle use [20]
- Digital clubbing — chronic finding but assess for progression
- ENT: Nasal polyps, sinus tenderness [1]
- Abdomen: Distension, RUQ tenderness (hepatomegaly), RLQ mass (DIOS)
- Extremities: Cyanosis, edema (cor pulmonale in advanced disease)
- Nutritional status: Muscle wasting, temporal wasting, BMI assessment [18]
11. Lab Studies
- Sputum culture and sensitivity — essential; request CF-specific processing (selective media for Pseudomonas, Burkholderia, Stenotrophomonas) [12][21]
- NTM culture — should be added routinely in patients >15 years presenting with exacerbation [21]
- CBC with differential [18]
- CRP — most validated blood biomarker; levels >9.5 mg/L discriminate exacerbation from stable state (Sn 76%, Sp 73%) [22-23]
- BMP/CMP — baseline renal function (pre-aminoglycoside), hepatic function (CFTR modulator monitoring), electrolytes [18]
- Blood glucose — glucose intolerance worsens during exacerbations; patients with CFRD require increased insulin [3]
- Aminoglycoside levels (trough and/or peak) — if IV tobramycin initiated [13]
- Serum IgE — if ABPA suspected [18]
12. Imaging
- Chest X-ray — first-line; assess for new infiltrates, lobar collapse, pneumothorax, mucus plugging [1][12]
- CT chest (HRCT) — gold standard for detailed assessment of bronchiectasis, mucus plugging, air trapping; not required for every exacerbation but valuable when CXR is equivocal or clinical response is poor [12][24]
- Lung ultrasound — emerging modality; superior to CXR for detecting consolidation and air bronchograms (AUROC 0.966 vs 0.483), comparable to HRCT, and avoids radiation [24]
- Imaging is unnecessary for mild exacerbations with expected clinical trajectory and known baseline imaging
13. Special Tests
- Spirometry (FEV₁, FVC) — compare to patient's baseline; ≥10% decline from baseline supports exacerbation diagnosis [1][20]
- Pulse oximetry — continuous if hypoxemic; ≥10% decline from baseline is a Fuchs criterion [20]
- Fuchs criteria — the most widely used diagnostic framework: requires ≥4 of 12 signs/symptoms (see above) [1]
- CFQ-R (Cystic Fibrosis Questionnaire-Revised) — validated patient-reported outcome for symptom severity and quality of life [13]
- Respiratory viral panel — consider multiplex PCR; viral co-infection identified in ~22% of exacerbations and associated with greater FEV₁ decline [4]
14. ECG
- Not routinely indicated for standard exacerbations
- Indications: Suspected pulmonary hypertension (right axis deviation, RV strain, P pulmonale), arrhythmia, or hemodynamic instability in advanced disease [10]
- QTc monitoring if using azithromycin + fluoroquinolone combination (QT prolongation risk)
15. Assessment
A CF pulmonary exacerbation is a clinical diagnosis based on a constellation of worsening respiratory symptoms, decline in lung function, and change from the patient's individual baseline. [3][13] No single test is diagnostic. Severity stratification guides treatment setting:
- Mild: Increased cough/sputum with minimal FEV₁ decline → may trial oral antibiotics and intensified airway clearance
- Moderate-severe: Significant FEV₁ decline (≥10%), systemic symptoms (fever, weight loss, fatigue), hypoxemia → IV antibiotics typically required [3][14]
- Complications to consider: Pneumothorax, massive hemoptysis, respiratory failure, ABPA, DIOS, CF-related diabetes decompensation [6][9][25]
In the HEMT era, exacerbations may present more subtly, and providers report expanding their assessment to identify milder phenotypes. [5]
16. Treatment Plan
Initial stabilization
- Supplemental O₂ to maintain SpO₂ ≥92%
- Intensify airway clearance (increase frequency and duration of chest physiotherapy, high-frequency oscillatory devices) [3][14]
Antibiotics
- IV dual therapy for moderate-severe exacerbations: aminoglycoside (tobramycin 10 mg/kg/day divided q8h or once-daily dosing per institutional protocol) + antipseudomonal β-lactam (piperacillin-tazobactam 4.5 g q8h, ceftazidime 2 g q8h, or meropenem 1 g q8h) — guided by most recent sputum culture [11][13]
- Oral ciprofloxacin may be appropriate for mild exacerbations [1]
- Duration: 10–14 days; early responders (by day 7–10) may complete 10 days; non-responders do not benefit from extending beyond 14 days [14]
Adjunctive therapies
- Continue dornase alfa, hypertonic saline, azithromycin [3]
- Continue CFTR modulators [5]
- Nutritional optimization: high-calorie, high-protein diet; dietitian consultation [14][16]
- Increase insulin dosing in patients with CFRD [3]
- Bronchodilators as needed
Complications management
- Massive hemoptysis: Hold airway clearance, correct coagulopathy, bronchial artery embolization [6]
- Pneumothorax: Chest tube drainage; avoid pleurodesis if transplant candidacy is being considered [6][8]
17. Disposition
Admission criteria
- Moderate-severe exacerbation requiring IV antibiotics
- Hypoxemia or respiratory distress
- Failure of outpatient oral antibiotic therapy
- Hemoptysis or pneumothorax
- Inability to perform adequate airway clearance at home
- Comorbidities complicating care (CFRD decompensation, renal dysfunction requiring drug monitoring) [3]
- Inadequate home resources for outpatient IV therapy [3]
Outpatient IV therapy may be considered if hospital-equivalent resources (airway clearance, nutrition, monitoring) can be assured at home — the CFF recommends against home IV therapy unless equivalent support is available [3]
Discharge criteria
- Clinical improvement in symptoms and spirometry
- Tolerating oral medications and adequate nutrition
- Stable oxygen saturation on room air (or baseline O₂)
- Completion of or transition plan for remaining IV antibiotic course
- Airway clearance regimen established
Specialist consultation: Pulmonology (CF center team) should be involved in all exacerbation management; interventional radiology for massive hemoptysis; thoracic surgery for recurrent pneumothorax [6]
18. Follow Up / Return Precautions
- Follow-up: CF center visit within 1–2 weeks of completing antibiotic course; repeat spirometry to assess FEV₁ recovery [3][11]
- ~44% of patients remain below baseline FEV₁ at 60 days post-treatment, underscoring the importance of close monitoring [11]
- Return precautions: Worsening dyspnea, new or increased hemoptysis, chest pain, fever despite antibiotics, inability to eat/drink, confusion or altered mental status
- Patient counseling: Reinforce adherence to airway clearance, CFTR modulators, and chronic suppressive antibiotics; infection control measures (avoid contact with other CF patients); influenza and COVID-19 vaccination [18]
- Expected course: Symptom improvement typically begins within 7–10 days of IV antibiotics; full FEV₁ recovery may take weeks and is not always achieved [11][14]
The following figure illustrates the temporal evolution of symptoms and FEV₁ decline before, during, and after IV antibiotic treatment for CF pulmonary exacerbation, highlighting that nocturnal cough emerges as the earliest warning sign (~17 days before treatment), followed by FEV₁ decline (~8 days before): [26]
References
1. Inhaled Antibiotics for Pulmonary Exacerbations in Cystic Fibrosis. — Smith S, Rowbotham NJ, Charbek E. The Cochrane Database of Systematic Reviews. 2022.
2. Digital Technology for Early Identification of Exacerbations in People With Cystic Fibrosis. — Wong CH, Smith S, Kansra S. The Cochrane Database of Systematic Reviews. 2023.
3. Cystic Fibrosis Pulmonary Guidelines: Treatment of Pulmonary Exacerbations. — Flume PA, Mogayzel PJ, Robinson KA, et al. American Journal of Respiratory and Critical Care Medicine. 2009.
4. Acute Pulmonary Exacerbation Phenotypes in Patients With Cystic Fibrosis. — Carter SC, Franciosi AN, O'Shea KM, et al. Annals of the American Thoracic Society. 2022.
5. Provider Practices in Pulmonary Exacerbations of Cystic Fibrosis in the Era of Highly Effective Modulator Therapy. — Toporek A, Patel S, Psoter KJ, et al. Annals of the American Thoracic Society. 2025.
6. Cystic Fibrosis Pulmonary Guidelines. — Patrick A. Flume, Peter J. Mogayzel, Karen A. Robinson, et al American Journal of Respiratory and Critical Care Medicine. 2010.
7. Cystic Fibrosis Foundation Consensus Guidelines for the Care of Individuals With Advanced Cystic Fibrosis Lung Disease. — Kapnadak SG, Dimango E, Hadjiliadis D, et al. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. 2020.
8. Pneumothorax in Cystic Fibrosis. — Kioumis IP, Zarogoulidis K, Huang H, et al. Journal of Thoracic Disease. 2014.
9. Critical Care of the Adult Patient With Cystic Fibrosis. — King CS, Brown AW, Aryal S, Ahmad K, Donaldson S. Chest. 2019.
10. Pulmonary Complications of Cystic Fibrosis. — Garcia B, Flume PA. Seminars in Respiratory and Critical Care Medicine. 2019.
11. Characteristics, Treatment, and Lung Function Outcomes of Pulmonary Exacerbations in Cystic Fibrosis: Insights From the BEAT-CF Cohort. — Fathima P, Pan E, Marsh J, et al. The European Respiratory Journal. 2025.
12. Cystic Fibrosis. — Shteinberg M, Haq IJ, Polineni D, Davies JC. Lancet. 2021.
13. Intravenous Antibiotics for Pulmonary Exacerbations in People With Cystic Fibrosis. — Hurley MN, Smith S, Flume P, Jahnke N, Prayle AP. The Cochrane Database of Systematic Reviews. 2025.
14. Cystic Fibrosis: A Review. — Ong T, Ramsey BW. The Journal of the American Medical Association. 2023.
15. Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. — Middleton PG, Mall MA, Dřevínek P, et al. The New England Journal of Medicine. 2019.
16. Cystic Fibrosis. — Grasemann H, Ratjen F. The New England Journal of Medicine. 2023.
17. Academy of Nutrition and Dietetics: 2020 Cystic Fibrosis Evidence Analysis Center Evidence-Based Nutrition Practice Guideline. — McDonald CM, Alvarez JA, Bailey J, et al. Journal of the Academy of Nutrition and Dietetics. 2021.
18. Cystic Fibrosis. — Savant A, Lyman B, Bojanowski C, et al GeneReviews® [Internet]. 2024.
19. Nutritional Considerations for a New Era: A CF Foundation Position Paper. — Leonard A, Bailey J, Bruce A, et al. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. 2023.
20. Duration of Intravenous Antibiotic Therapy in People With Cystic Fibrosis. — Abbott L, Plummer A, Hoo ZH, Wildman M. The Cochrane Database of Systematic Reviews. 2019.
21. Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM). — Miller JM, Binnicker MJ, Campbell S, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2024.
22. Circulating CRP and Calprotectin to Diagnose CF Pulmonary Exacerbations. — Jung D, Dong K, Jang J, et al. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. 2021.
23. Systematic Review of Blood Biomarkers in Cystic Fibrosis Pulmonary Exacerbations. — Shoki AH, Mayer-Hamblett N, Wilcox PG, Sin DD, Quon BS. Chest. 2013.
24. Lung Ultrasound for the Diagnosis of Cystic Fibrosis Pulmonary Exacerbation. — Hassanzad M, Kiani A, Abedini A, et al. BMC Pulmonary Medicine. 2021.
25. Pulmonary Complications in Cystic Fibrosis: Past, Present, and Future: Adult Cystic Fibrosis Series. — Mingora CM, Flume PA. Chest. 2021.
26. Home‐spirometry exacerbation profiles in children with cystic fibrosis. — Bouteleux B, Beaufils F, Fayon M, Bui S. Pediatric Pulmonology. 2024.